News
Padcev/Keytruda scores again in early bladder cancer
Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.
Oncology
ESMO25: Perspective on ‘inside-out oncology’ and targeted al...
Perspective Therapeutics is advancing image‑guided, targeted alpha‑particle therapies (TATs). We spoke to Thijs Spoor at ESMO 2025 to find out more.
News
Enhertu moves into frontline breast cancer treatment
Daiichi Sankyo and AstraZeneca's Enhertu has become the first new first-line option in the US for HER2-positive breast cancer in more than a decade.
News
J&J claims FDA's latest national priority voucher
The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.
Oncology
How blood tests can inform cancer treatment decisions, with ...
Craig Eagle, chief medical officer of Guardant Health, discusses blood as a rich source of biomarker development in cancer prognosis.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
